This indicated that there may be an increased risk of fetal loss in the first trimester of pregnancy.There is no evidence of an increased risk of severe congenital abnormality.
There are only 3 recent reports of nosocomial transmission of mumps in the published literature.
In all 3, none of the control measures instituted appeared to be highly effective in preventing onward transmission.
Generally, live virus vaccines are contraindicated for pregnant women because of the theoretical risk of transmission of the vaccine virus to the fetus.
vaccine have been given inadvertently to pregnant women with no ill effects observed.
There are currently no recommendations for excluding women from such settings for the following reasons: There may be specific circumstances that make the risk to a pregnancy of contracting mumps higher for particular individuals. There is no evidence, that we are aware of, to support the use of human normal immunoglobulin for contacts of cases as this has not been shown to have any benefit.
There is no evidence we are aware of that pregnant women are at any higher risk of complications of mumps than other adults and no specific treatment other than supportive is recommended.The evidence base for an increased risk of fetal loss due to mumps in pregnancy is weak.There are no available interventions to reduce any possible risk to the fetus.Indeed, the only case series in leukaemic patients suggests that mumps may follow a milder course in such groups.Clearly the best way to prevent such incidents is by maintaining high vaccine uptake in the community.There are limited data on the outcome of mumps in immunocompromised patients.